vs
Amalgamated Financial Corp.（AMAL）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是Amalgamated Financial Corp.的2.0倍（$168.4M vs $85.2M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 9.4%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 4.3%）
CI金融集团是一家总部位于加拿大安大略省多伦多的投资管理公司，面向高净值个人投资者提供投资管理与财富管理服务，同时也为投资组合经理及机构投资者提供经纪与交易服务。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
AMAL vs ESPR — 直观对比
营收规模更大
ESPR
是对方的2.0倍
$85.2M
营收增速更快
ESPR
高出134.3%
9.4%
两年增速更快
ESPR
近两年复合增速
4.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $85.2M | $168.4M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | 39.0% | 50.6% |
| 净利率 | — | — |
| 营收同比 | 9.4% | 143.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.88 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMALESPR
| Q4 25 | $85.2M | $168.4M | ||
| Q3 25 | $85.6M | $87.3M | ||
| Q2 25 | $80.9M | $82.4M | ||
| Q1 25 | $77.0M | $65.0M | ||
| Q4 24 | $77.9M | $69.1M | ||
| Q3 24 | $81.0M | $51.6M | ||
| Q2 24 | $78.5M | $73.8M | ||
| Q1 24 | $78.3M | $137.7M |
净利润AMALESPR
| Q4 25 | — | — | ||
| Q3 25 | $26.8M | $-31.3M | ||
| Q2 25 | $26.0M | $-12.7M | ||
| Q1 25 | $25.0M | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $27.9M | $-29.5M | ||
| Q2 24 | $26.8M | $-61.9M | ||
| Q1 24 | $27.2M | $61.0M |
营业利润率AMALESPR
| Q4 25 | 39.0% | 50.6% | ||
| Q3 25 | 42.9% | -11.4% | ||
| Q2 25 | 43.8% | 8.6% | ||
| Q1 25 | 45.1% | -34.0% | ||
| Q4 24 | 42.4% | -6.4% | ||
| Q3 24 | 47.2% | -31.0% | ||
| Q2 24 | 45.6% | 3.5% | ||
| Q1 24 | 49.2% | 52.5% |
净利率AMALESPR
| Q4 25 | — | — | ||
| Q3 25 | 31.3% | -35.9% | ||
| Q2 25 | 32.1% | -15.4% | ||
| Q1 25 | 32.5% | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 34.5% | -57.2% | ||
| Q2 24 | 34.1% | -83.9% | ||
| Q1 24 | 34.8% | 44.3% |
每股收益（稀释后）AMALESPR
| Q4 25 | $0.88 | $0.32 | ||
| Q3 25 | $0.88 | $-0.16 | ||
| Q2 25 | $0.84 | $-0.06 | ||
| Q1 25 | $0.81 | $-0.21 | ||
| Q4 24 | $0.78 | $-0.14 | ||
| Q3 24 | $0.90 | $-0.15 | ||
| Q2 24 | $0.87 | $-0.33 | ||
| Q1 24 | $0.89 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $291.2M | $167.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $794.5M | $-302.0M |
| 总资产 | $8.9B | $465.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMALESPR
| Q4 25 | $291.2M | $167.9M | ||
| Q3 25 | $115.5M | $92.4M | ||
| Q2 25 | $171.1M | $86.1M | ||
| Q1 25 | $65.7M | $114.6M | ||
| Q4 24 | $60.7M | $144.8M | ||
| Q3 24 | $149.2M | $144.7M | ||
| Q2 24 | $58.0M | $189.3M | ||
| Q1 24 | $155.2M | $226.6M |
股东权益AMALESPR
| Q4 25 | $794.5M | $-302.0M | ||
| Q3 25 | $775.6M | $-451.4M | ||
| Q2 25 | $754.0M | $-433.5M | ||
| Q1 25 | $736.0M | $-426.2M | ||
| Q4 24 | $707.7M | $-388.7M | ||
| Q3 24 | $698.2M | $-370.2M | ||
| Q2 24 | $646.0M | $-344.2M | ||
| Q1 24 | $616.8M | $-294.3M |
总资产AMALESPR
| Q4 25 | $8.9B | $465.9M | ||
| Q3 25 | $8.7B | $364.0M | ||
| Q2 25 | $8.6B | $347.1M | ||
| Q1 25 | $8.3B | $324.0M | ||
| Q4 24 | $8.3B | $343.8M | ||
| Q3 24 | $8.4B | $314.1M | ||
| Q2 24 | $8.3B | $352.3M | ||
| Q1 24 | $8.1B | $373.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $135.8M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | $134.4M | — |
| 自由现金流率自由现金流/营收 | 157.8% | — |
| 资本支出强度资本支出/营收 | 1.6% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $229.4M | — |
8季度趋势，按日历期对齐
经营现金流AMALESPR
| Q4 25 | $135.8M | $45.2M | ||
| Q3 25 | $39.5M | $-4.3M | ||
| Q2 25 | $24.9M | $-31.4M | ||
| Q1 25 | $34.2M | $-22.6M | ||
| Q4 24 | $124.1M | $-35.0M | ||
| Q3 24 | $35.8M | $-35.3M | ||
| Q2 24 | $28.0M | $-7.2M | ||
| Q1 24 | $31.3M | $53.8M |
自由现金流AMALESPR
| Q4 25 | $134.4M | — | ||
| Q3 25 | $38.3M | — | ||
| Q2 25 | $24.2M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $122.3M | — | ||
| Q3 24 | $35.2M | $-35.5M | ||
| Q2 24 | $27.8M | $-7.3M | ||
| Q1 24 | $31.1M | $53.8M |
自由现金流率AMALESPR
| Q4 25 | 157.8% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 29.9% | — | ||
| Q1 25 | 42.2% | — | ||
| Q4 24 | 157.0% | — | ||
| Q3 24 | 43.4% | -68.7% | ||
| Q2 24 | 35.4% | -9.9% | ||
| Q1 24 | 39.7% | 39.0% |
资本支出强度AMALESPR
| Q4 25 | 1.6% | 0.0% | ||
| Q3 25 | 1.4% | 0.0% | ||
| Q2 25 | 0.9% | 0.0% | ||
| Q1 25 | 2.3% | 0.0% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 0.7% | 0.3% | ||
| Q2 24 | 0.3% | 0.1% | ||
| Q1 24 | 0.3% | 0.1% |
现金转化率AMALESPR
| Q4 25 | — | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.96× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.05× | — | ||
| Q1 24 | 1.15× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMAL
暂无分部数据
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
